Modus Therapeutics Holding AB (OSTO:MODTX) Interest Expense: kr-0.31 Mil (TTM As of Mar. 2026)


OSTO:MODTX Modus Therapeutics Holding AB OSTO:MODTX
30 GF Score
Price kr0.37
! 1 Warning Sign
View Full Analysis

What is Modus Therapeutics Holding AB Interest Expense?

Modus Therapeutics Holding AB OSTO:MODTX +0.54% 30 Interest Expense is kr-0.31 Mil as of Mar. 2026. GuruFocus rates OSTO:MODTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Modus Therapeutics Holding AB's interest expense for the three months ended in Mar. 2026 was kr 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.31 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Modus Therapeutics Holding AB's Operating Income for the three months ended in Mar. 2026 was kr -3.28 Mil. Modus Therapeutics Holding AB's Interest Expense for the three months ended in Mar. 2026 was kr 0.00 Mil. Modus Therapeutics Holding AB has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Modus Therapeutics Holding AB  (OSTO:MODTX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Modus Therapeutics Holding AB's Interest Expense for the three months ended in Mar. 2026 was kr0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was kr-3.28 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was kr0.00 Mil.

Modus Therapeutics Holding AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Modus Therapeutics Holding AB had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Modus Therapeutics Holding AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Modus Therapeutics Holding AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modus Therapeutics Holding AB Interest Expense Chart

Modus Therapeutics Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.00 -0.31 -1.50 0.00 -0.41

Modus Therapeutics Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.19 -0.12 -0.00 0.00
OSTO:MODTX
30GF Score
Modus Therapeutics Holding AB OSTO:MODTX
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Modus Therapeutics Holding AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr-0.31 Mil mean?
Modus Therapeutics Holding AB (OSTO:MODTX) has a Interest Expense of kr-0.31 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Modus Therapeutics Holding AB and its competitors.
Is Modus Therapeutics Holding AB's Interest Expense too high?
Modus Therapeutics Holding AB's current Interest Expense is kr-0.31 Mil. Overall, Modus Therapeutics Holding AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Modus Therapeutics Holding AB's Interest Expense compare to VRTX and REGN?
Modus Therapeutics Holding AB's Interest Expense of kr-0.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Modus Therapeutics Holding AB and its competitors. Modus Therapeutics Holding AB's current Interest Expense is kr-0.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modus Therapeutics Holding AB stock overvalued right now?
Modus Therapeutics Holding AB (OSTO:MODTX) has a current Interest Expense of kr-0.31 Mil. The current Interest Expense is kr-0.31 Mil. Modus Therapeutics Holding AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Modus Therapeutics Holding AB (OSTO:MODTX), the current Interest Expense is kr-0.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modus Therapeutics Holding AB Business Description

Address Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
30GF Score

Get the complete analysis for OSTO:MODTX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.37
Price